Ultragenyx Pharmaceutical Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for RARE, updated each market day.
RARE AI Sentiment
AI sees no strong directional signal for Ultragenyx Pharmaceutical Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Sector
Exchange
Market Cap
$2,350,764,754
Cap Tier
Employees
1,371
Headquarters
NOVATO, CA
Listed Since
Jan. 31, 2014
Website
RARE Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RARE Volatility
Ultragenyx Pharmaceutical Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
